Redmile Group, LLC Biogen Inc. Transaction History

Redmile Group, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$259.0 - $414.71 $42.2 Million - $67.5 Million	-162,847 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$242.95 - $284.63 $13 Million - $15.2 Million	-53,400 Reduced 24.69%	162,847 $45.6 Million
Q4 2020 Feb 16, 2021	SELL	$236.26 - $355.63 $26.3 Million - $39.5 Million	-111,200 Reduced 33.96%	216,247 $53 Million
Q3 2020 Nov 16, 2020	BUY	$264.77 - $305.71 $43.7 Million - $50.5 Million	165,147 Added 101.75%	327,447 $92.9 Million
Q2 2020 Aug 14, 2020	SELL	$258.66 - $342.55 $110 Million - $146 Million	-427,000 Reduced 72.46%	162,300 $43.4 Million
Q1 2020 May 15, 2020	BUY	$268.85 - $341.04 $35.4 Million - $44.9 Million	131,800 Added 28.81%	589,300 $186 Million
Q4 2019 Feb 14, 2020	BUY	$220.06 - $304.07 $101 Million - $139 Million	457,500 New	457,500 $136 Million
Q2 2019 Aug 14, 2019	SELL	$219.29 - $241.72 $36.2 Million - $40 Million	-165,300 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$216.71 - $338.96 $35.8 Million - $56 Million	165,300 New	165,300 $39.1 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.